ALB and glomerulosclerosis: Moreover, after adjusting a variety of possible confounding factors, including demographics and anthropometrics (age, sex, and MAP), follow-up treatments (ACEi/ARB, glucocorticoids, and immunosuppressants), kidney pathology (crescents, glomerulosclerosis), and laboratory results (eGFR, urine albumin, etc.)as listed in Table 2, the hazard ratio of SPS for ESRD only remained significant in the IgAN group (HR 8.35, 95% CI: 2.10~33.26).